Immunovant, Inc. 4

CTO Jay S. Stout sold 2,857 shares of Immunovant, Inc. common stock for about $110K in a mandatory sell-to-cover transaction tied to RSU vesting, leaving him with 205,341 shares.

On July 23, 2026, Immunovant, Inc. Chief Technology Officer Jay S. Stout reported the sale of 2,857 shares of Immunovant common stock at a weighted average price of approximately $38.69 per share, for proceeds of about $110,447. This sale was executed solely to cover tax withholding obligations arising from the July 17, 2026 vesting and settlement of a previously granted 100,000-RSU award (of which 6,250 RSUs vested on that date) and was carried out under the issuer’s mandatory sell-to-cover policy rather than as a discretionary trade. Following the transaction, Stout beneficially owned 205,341 shares of Immunovant common stock. Using the reported transaction price as a proxy, his post-transaction holdings are worth roughly $7.94 million.

Filing Facts

CIK

1764013

Ticker

IMVT

Form

4

Source Type

fda

Accession

0001702969-26-000010

Alert Tier

5